Neratinib: First Global Approval. - Wikidata - wikimedia - TriplyDB

Neratinib: First Global Approval.

Neratinib: First Global Approval.

http://www.wikidata.org/entity/Q50201250

about

Highlights from the 10th Breast, Gynaecological and Immunotherapy International Cancer Conference (BGICC), 18-19 January 2018, Cairo, Egypt.

P2860

Q53692410-443FB6EB-D4AE-4CE0-B04A-05955E89533E

P2860

Neratinib: First Global Approval.

http://www.wikidata.org/entity/Q50201250

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Neratinib: First Global Approval.

@en

Neratinib: First Global Approval.

@nl

type

label

Neratinib: First Global Approval.

@en

Neratinib: First Global Approval.

@nl

prefLabel

Neratinib: First Global Approval.

@en

Neratinib: First Global Approval.

@nl

P1433

Q50201250-ABB6CB15-B0C5-4A79-B614-345C2D35155D

P1476

Q50201250-C966DE43-5033-4700-9F8B-5650A665A7DD

P2093

Q50201250-87BD797C-D68E-4B77-8380-5723EE0D053F

P2860

Q50201250-0229C052-4EF1-4C45-8D00-52D2A2E5AAA7

Q50201250-0B04BCCB-A12F-44F3-91C9-8BB430AD03D6

Q50201250-0E0DCF0E-E293-4F7C-9E45-137C8FE1672F

Q50201250-1ACF7978-C3EC-4D33-911B-90C415892397

Q50201250-27C78EF4-FBEE-4EBF-894A-BCA6B546A4FB

Q50201250-27F5A3B2-43AB-4C4B-8859-0233B58ABE4C

Q50201250-2EA95FE7-BBD6-4E20-999A-A72A99FCC484

Q50201250-3631853F-FC58-409F-9C74-87DD2F61DDBB

Q50201250-37CCDB91-7700-4BC8-BD1E-140B50A385B9

Q50201250-388B9DD6-7D4C-4CBE-8830-86713EDEFBAE

P2888

Q50201250-6FFD77C6-9296-4A6B-9C91-0869DCE00CE8

P304

Q50201250-B5F415DA-E92A-40B7-ABA0-84CFF7B09CEA

P31

Q50201250-B8FD4F65-74C9-41E1-BE14-BCE1BCC477A4

P356

Q50201250-0A04AC1C-BA86-4E9E-9AF4-7DF91216249A

P433

Q50201250-40A93402-7844-4FD7-BCEE-7CB1A2A8FE4C

P478

Q50201250-A846381E-C7CE-4AFD-BA96-A08C440C3403

P577

Q50201250-542E9237-9875-4665-8752-9539E1F7BB94

P698

Q50201250-C6797443-B96C-4431-974D-D76F436AE8B5

P356

S40265-017-0811-4

P1433

P1476

Neratinib: First Global Approval.

@en

P2093

Emma D Deeks

http://www.w3.org/2001/XMLSchema#string

P2860

Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer.

Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.

HER2 somatic mutations are associated with poor survival in HER2-negative breast cancers

The role of HER2 in cancer therapy and targeted drug delivery

Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers: Overexpression and Therapeutic Implications

Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase.

Pharmacokinetics of oral neratinib during co-administration of ketoconazole in healthy subjects

Neratinib reverses ATP-binding cassette B1-mediated chemotherapeutic drug resistance in vitro, in vivo, and ex vivo.

Neratinib shows efficacy in the treatment of HER2 amplified carcinosarcoma in vitro and in vivo.

Dual HER2/PIK3CA Targeting Overcomes Single-Agent Acquired Resistance in HER2-Amplified Uterine Serous Carcinoma Cell Lines In Vitro and In Vivo.

P2888

s40265-017-0811-4

P304

1695-1704

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S40265-017-0811-4

http://www.w3.org/2001/XMLSchema#string

P433

15

http://www.w3.org/2001/XMLSchema#string

P478

77

http://www.w3.org/2001/XMLSchema#string

P577

2017-09-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28884417

http://www.w3.org/2001/XMLSchema#string